Assessee sold 22,62,512 equity shares of J.B. Chemicals and Pharmaceuticals Ltd. (JBCPL) to Tau Investment Holdings Pte. Ltd. for ₹168.55 crore. He claimed the transaction was genuine and supported by documentation, including regulatory approvals from SEBI and the Competition Commission of India. The Assessing Officer  questioned the genuineness and creditworthiness of Tau Investment and made addition u/s 68 of the Act . CIT(A) deleted the addition. On appeal by Revenue  the Tribunal held that  The Tribunal agreed with the CIT(A) that the transaction was genuine which is supported by share purchase agreement, Letter of Offer to SEBI, and confirmation from Tau Investment and the transaction was part of a larger acquisition by KKR Group. The Tribunal rejected the Revenue’s arguments of inadequate evidence, noting that the AO did not pursue direct inquiries with Tau Investment despite being provided with contact details. Order of CIT (A) is affirmed .  (ITA No.1085 /Mum/2024 dt .13-1 -2025 )(AY. 2021 -22 )